Suppression of estrogen receptor transcriptional activity by connective tissue growth factor

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Cheng, Long ^a   Yang, Zhihong ^a   Wang, Xiaohui ^a   Jiao, Yuanyuan ^a   Xie, Xiangyang ^a   Lin, Jing ^b   Zhang, Hao ^a   Han, Juqiang ^a   Jiang, Kai ^a   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; CELL ADHESION; CONTROLLED STUDY; DNA BINDING; GENE ACTIVITY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; REPORTER GENE; TRANSCRIPTION REGULATION; YEAST CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TWO HYBRID SYSTEM; WESTERN BLOTTING;

BLOTTING, WESTERN; CONNECTIVE TISSUE GROWTH FACTOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 79956344763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020028     Document Type: Article

References (48)

1. Hanstein B, Djahansouzi S, Dall P, Beckmann MW, Bender HG, (2004) Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. Eur J Endocrinol 150: 243-255.
2. Deroo BJ, Korach KS, (2006) Estrogen receptors and human disease. J Clin Invest 116: 561-570.
3. Klinge CM, (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905-2919.
4. Levin ER, Pietras RJ, (2008) Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108: 351-361.
5. Jacob J, Sebastian KS, Devassy S, Priyadarsini L, Farook MF, et al. (2006) Membrane estrogen receptors: genomic actions and post transcriptional regulation. Mol Cell Endocrinol 246: 34-41.
6. Ignar-Trowbridge DM, Pimentel M, Teng CT, Korach KS, McLachlan JA, (1995) Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ Health Perspect 103: 35-38.
7. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331s-336s.
8. Bork P, (1993) The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327: 125-130.
9. Brigstock DR, (2003) The CCN family: a new stimulus package. J Endocrinol 178: 169-175.
10. Perbal B, (2004) CCN proteins: multifunctional signalling regulators. Lance 363: 62-64.
11. Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, et al. (2006) Effect of connective tissue growth factor on hypoxia-inducible factor 1 degradation and tumor angiogenesis. J Natl Cancer Inst 98: 984-995.
12. Han J, Ding L, Yuan B, Yang X, Wang X, et al. (2006) Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells. Nucleic Acids Res 34: 3095-3106.
13. Ding L, Yan J, Zhu J, Zhong H, Lu Q, et al. (2003) Ligand-independent activation of estrogen receptor α by XBP-1. Nucleic Acids Res 31: 5266-5274.
14. Gobinet J, Auzou G, Nicolas JC, Sultan C, Jalaguier S, (2001) Characterization of the interaction between androgen receptor and a new transcription inhibitor, SHP. Biochemistry 2001, 40: 15369-15377.
15. Zhang H, Xie X, Zhu X, Zhu J, Hao C, et al. (2005) Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem 280: 43188-43197.
16. Qin X, Wang XH, Yang ZH, Ding LH, Xu XJ, et al. (2008) Repression of NFAT3 transcriptional activity by estrogen receptors. Cell Mol Life Sci 65: 2752-2762.
17. Ding L, Wang Z, Yan J, Yang X, Liu A, et al. (2009) Human four-and-a-half LIM family members suppress tumor cell growth through a TGFβ-like signaling pathway. J Clin Invest 119: 349-361.
18. Tateishi Y, Kawabe YI, Chiba T, Murata S, Ichikawa K, et al. (2004) Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23: 4813-4823.
19. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, et al. (2006) Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 5: 611-620.
20. Levin ER, (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19: 1951-1959.
21. Pietras RJ, Szego CM, (1980) Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochem J 191: 743-760.
22. Pappas TC, Gametchu B, Watson CS, (1995) Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 9: 404-410.
23. Razandi M, Pedram A, Greene GL, Levin ER, (1999) Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol 13: 307-319.
24. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, et al. (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc Natl Acad Sci 101: 2076-2081.
25. Lichtner RB, (2003) Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 57: 447-451.
26. Klinge CM, (2000) Estrogen receptor interaction with co-activators and co-repressors. Steroids 65: 227-251.
27. Hall JM, McDonnell DP, (2005) Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5: 343-357.
28. Loven MA, Muster N, Yates JR, Nardulli AM, (2003) A novel estrogen receptor alpha-associated protein, template-activating factor Ibeta, inhibits acetylation and transactivation. Mol Endocrinol 17: 67-78.
29. Loven MA, Davis RE, Curtis CD, Muster N, Yates JR, et al. (2004) A novel estrogen receptor α-associated protein alters receptor-deoxyribonucleic acid interactions and represses receptor-mediated transcription. Mol Endocrinol 18: 2649-2659.
30. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, et al. (2006) ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res 34: 6126-6136.
31. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-v 3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120: 2053-2065.
32. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR 3rd, et al. (2001) The low density lipoprotein receptor-related protein/2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 276: 40659-40667.
33. Mercurio S, Latinkic B, Itasaki N, Krumlauf R, Smith JC, (2004) Connective-tissue growth factor modulates WNT signaling and interacts with the WNT receptor complex. Development 131: 2137-2147.
34. Kouzmenko AP, Takeyama KI, Ito S, Furutani T, Sawatsubashi S, et al. (2004) Wnt/β-catenin and estrogen signaling converge in vivo. J Biol Chem 279: 40255-40258.
35. Shi B, Liang J, Yang X, Wang Y, Zhao Y, et al. (2007) Integration of estrogen and Wnt signaling circuits by the Polycomb Group Protein EZH2 in breast cancer cells. Mol Cell Biol 27: 5105-5119.
36. Hou X, Tan Y, Li M, Dey SK, Das SK, (2004) Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol 18: 3035-3049.
37. Forda CE, Ekstroma EJ, Anderssona T, (2009) Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci 106: 3919-3924.
38. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, et al. (2005) Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 65: 8887-8895.
39. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, et al. (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10: 2072-2081.
40. Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, et al. (2007) Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through-catenin-T-cell factor/Lef signaling. J Biol Chem 282: 36571-36581.
41. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, et al. (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE 2: e534.
42. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, et al. (2005) Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 128: 9-23.
43. Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, et al. (2007) Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 67: 7095-7105.
44. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, et al. (2004) Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 11: 781-791.
45. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP, (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917-23.
46. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, et al. (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274: 37461-37466.
47. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
48. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T, (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 458: 187-193.